Jane Street Group LLC Makes New Investment in Strongbridge Biopharma plc (NASDAQ:SBBP)

Share on StockTwits

Jane Street Group LLC purchased a new position in shares of Strongbridge Biopharma plc (NASDAQ:SBBP) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 82,040 shares of the biotechnology company’s stock, valued at approximately $257,000. Jane Street Group LLC owned approximately 0.15% of Strongbridge Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. JPMorgan Chase & Co. purchased a new position in shares of Strongbridge Biopharma during the second quarter worth approximately $42,000. Alambic Investment Management L.P. purchased a new position in shares of Strongbridge Biopharma during the second quarter worth approximately $66,000. Northern Trust Corp purchased a new position in shares of Strongbridge Biopharma during the second quarter worth approximately $96,000. Parametric Portfolio Associates LLC purchased a new position in shares of Strongbridge Biopharma during the second quarter worth approximately $112,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of Strongbridge Biopharma during the second quarter worth approximately $236,000. 52.25% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ SBBP opened at $2.01 on Friday. Strongbridge Biopharma plc has a 52 week low of $2.00 and a 52 week high of $6.52. The firm’s fifty day moving average is $2.53 and its 200 day moving average is $3.20. The company has a market cap of $116.50 million, a price-to-earnings ratio of 4.78 and a beta of 0.81.

Strongbridge Biopharma (NASDAQ:SBBP) last issued its earnings results on Wednesday, July 31st. The biotechnology company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.01. Strongbridge Biopharma had a net margin of 181.52% and a return on equity of 49.92%. The company had revenue of $6.08 million for the quarter, compared to the consensus estimate of $4.82 million. As a group, equities analysts predict that Strongbridge Biopharma plc will post -1.19 EPS for the current year.

Several research firms have commented on SBBP. HC Wainwright reissued a “buy” rating on shares of Strongbridge Biopharma in a research note on Thursday, August 1st. ValuEngine raised shares of Strongbridge Biopharma from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 2nd. Jefferies Financial Group began coverage on shares of Strongbridge Biopharma in a research note on Tuesday, September 24th. They set a “buy” rating and a $8.00 price target on the stock. Zacks Investment Research downgraded shares of Strongbridge Biopharma from a “buy” rating to a “hold” rating in a research note on Friday, August 2nd. Finally, Evercore ISI assumed coverage on shares of Strongbridge Biopharma in a research note on Tuesday, September 24th. They issued an “outperform” rating on the stock. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $9.90.

About Strongbridge Biopharma

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.

Featured Article: How are the companies in the S&P 500 selected?

Want to see what other hedge funds are holding SBBP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Strongbridge Biopharma plc (NASDAQ:SBBP).

Institutional Ownership by Quarter for Strongbridge Biopharma (NASDAQ:SBBP)

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.